Jci_page_head_homepage_01 Jci_page_head_homepage_02
Noriaki Okamoto, Risa Chihara, Chiori Shimizu, Sogo Nishimoto, Takeshi Watanabe
Published in Volume 117, Issue 4
J Clin Invest. 2007; 117(4):997–1007 doi:10.1172/JCI30379
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4
Increased number of IgG1 NP-specific AFCs in aLN-transplanted SCID mice after immunization with NP-OVA.

(A and B) Number of NP-specific IgG AFCs in aLNs (A) or spleens (B) of aLN-transplanted SCID mice. Mice were immunized i.v. with NP-OVA on days 1 and 7 (100 μg/mouse and 10 μg/mouse, respectively) after transplantation of aLNs into SCID mice on day 0. The number of lymphocytes in spleens of aLN-transplanted SCID mice before and after NP-OVA immunization is denoted by the line (B). (C) Upon the second antigen stimulation, large numbers of IgG1 NP-specific AFCs were also detected in the BM of aLN-transplanted SCID mice. (D) Number of NP-specific IgG AFCs in spleens of recipient SCID and BALB/c mice. (E and F) Number of NP-specific IgG AFCs in aLNs (E) or spleens (F) of aLN-transplanted SCID mice immunized i.v. with NP-OVA on days 7 and 14 (100 μg/mouse and 10 μg/mouse, respectively) after transplantation of aLNs into SCID mice on day 0. The number of lymphocytes in spleens of aLN-transplanted SCID mice before and after NP-OVA immunization is denoted by the line (F).